GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marvel Biosciences Corp (OTCPK:MBCOF) » Definitions » Net-Net Working Capital

MBCOF (Marvel Biosciences) Net-Net Working Capital : $-0.06 (As of Jan. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Marvel Biosciences Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Marvel Biosciences's Net-Net Working Capital for the quarter that ended in Jan. 2025 was $-0.06.

The industry rank for Marvel Biosciences's Net-Net Working Capital or its related term are showing as below:

MBCOF's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 4.12
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Marvel Biosciences Net-Net Working Capital Historical Data

The historical data trend for Marvel Biosciences's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marvel Biosciences Net-Net Working Capital Chart

Marvel Biosciences Annual Data
Trend Jul20 Jul21 Jul22 Jul23 Jul24
Net-Net Working Capital
- 0.06 - -0.03 -0.05

Marvel Biosciences Quarterly Data
Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.05 -0.05 -0.05 -0.06

Competitive Comparison of Marvel Biosciences's Net-Net Working Capital

For the Biotechnology subindustry, Marvel Biosciences's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marvel Biosciences's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marvel Biosciences's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Marvel Biosciences's Price-to-Net-Net-Working-Capital falls into.


;
;

Marvel Biosciences Net-Net Working Capital Calculation

Marvel Biosciences's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Jul. 2024 is calculated as

Net-Net Working Capital(A: Jul. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.252+0.75 * 0+0.5 * 0-2.419
-0-0)/44.786
=-0.05

Marvel Biosciences's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jan. 2025 is calculated as

Net-Net Working Capital(Q: Jan. 2025 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.042+0.75 * 0+0.5 * 0-2.617
-0-0)/44.804
=-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Marvel Biosciences  (OTCPK:MBCOF) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Marvel Biosciences Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Marvel Biosciences's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Marvel Biosciences Business Description

Traded in Other Exchanges
Address
505 - 8th Avenue SW, Suite 420, Calgary, AB, CAN, T2P1G2
Marvel Biosciences Corp is a life sciences company focused on the discovery and development of a synthetic derivative compound of a known drug. It has developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.